The United States Food and Drug Administration (FDA) has sent a formal warning letter to Novo Nordisk regarding significant lapses in their reporting of adverse effects related to two of their popular medications: Ozempic and Wegovy, both of which are based on semaglutide. This warning, dated March 5, 2026, follows an inspection that took place between January 13 and February 7, 2025, at the company's facility in Plainsboro, New Jersey. The FDA's concerns stem from Novo Nordisk's failure to meet required deadlines and processes for reporting serious and unexpected adverse experiences, as mandated by U.S. regulations.

Among the key findings of the FDA inspection were issues with Novo Nordisk's internal procedures that allowed for the dismissal of reports when consumers claimed there was no apparent relationship to the treatment. This raises concerns about patient safety and the reliability of the data being reported. The agency highlighted that such lapses in reporting can lead to a public health risk, especially given the widespread use of these medications for weight management and diabetic treatment.

The implications of this warning are significant for Novo Nordisk, as it may face regulatory scrutiny and potential penalties if these issues are not resolved promptly. Furthermore, it could affect public perception of the company and its commitment to ensuring drug safety. The situation underscores the importance of rigorous adherence to reporting standards in the pharmaceutical industry, particularly as the FDA aims to protect public health and safety.